BRUCE C. COZADD - 26 Nov 2025 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
Director
Signature
By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd
Issuer symbol
JAZZ
Transactions as of
26 Nov 2025
Transactions value $
-$4,219,937
Form type
4
Filing time
01 Dec 2025, 18:14:23 UTC
Previous filing
20 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
COZADD BRUCE C Director 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, IRELAND By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd 01 Dec 2025 0001193210

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Options Exercise $9.46M +76.7K +19.5% $123.36 470K 26 Nov 2025 Direct
transaction JAZZ Ordinary Shares Options Exercise $100K +811 +0.17% $123.36 471K 26 Nov 2025 Direct
transaction JAZZ Ordinary Shares Sale -$5.43M -30.5K -6.48% $178.06 440K 26 Nov 2025 Direct F1
transaction JAZZ Ordinary Shares Sale -$1.5M -8.38K -1.9% $179.23 432K 26 Nov 2025 Direct F2
transaction JAZZ Ordinary Shares Sale -$91.2K -507 -0.12% $179.79 431K 26 Nov 2025 Direct F3
transaction JAZZ Ordinary Shares Sale -$6.76M -38.1K -8.84% $177.27 393K 26 Nov 2025 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAZZ Incentive Stock Option (right to buy) Options Exercise $0 -811 -100% $0.00 0 26 Nov 2025 Ordinary Shares 811 $123.36 Direct F5
transaction JAZZ Non-Qualified Stock Option (right to buy) Options Exercise $0 -76.7K -100% $0.00 0 26 Nov 2025 Ordinary Shares 76.7K $123.36 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $177.70 to $178.685. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $178.72 to $179.705. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3 Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $179.73 to $179.96. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.70 to $177.69. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5 These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.